Treatment of Sleep Related Breathing Disorders in Patients With Pulmonary Hypertension

NCT ID: NCT01427192

Last Updated: 2012-12-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

23 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-11-30

Study Completion Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to study the differential short-term effect of nocturnal oxygen, acetazolamide tablets and nocturnal non-invasive positive pressure ventilation on symptoms, exercise capacity and nocturnal breathing disturbances in subjects with pulmonary hypertension and sleep related breathing disorders

* Trial with medicinal product

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Hypertension Breathing-Related Sleep Disorder

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Breathing-Related Sleep Disorder Pulmonary Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

acetazolamide

1 week therapy, cross-over design

Group Type EXPERIMENTAL

acetazolamide

Intervention Type DRUG

250 mg bid

Placebo tablet

One week, cross-over design

Group Type PLACEBO_COMPARATOR

Placebo tablet

Intervention Type DRUG

Placebo tablet (Mannitol) similar to acetazolamide

supplemental oxygen during nights

One week, cross-over design

Group Type EXPERIMENTAL

Supplemental oxygen

Intervention Type OTHER

Oxygen deliverded by nasal cannula

Non-invasive ventilation

One week, cross-over design

Group Type EXPERIMENTAL

Non-invasive ventilation

Intervention Type PROCEDURE

Bi-level non-invasive ventilation via nasal mask

room air

room air applied via sham-oxygen-concentrator

Group Type SHAM_COMPARATOR

Room air

Intervention Type OTHER

Room air applied via sham oxygen concentrator

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

acetazolamide

250 mg bid

Intervention Type DRUG

Supplemental oxygen

Oxygen deliverded by nasal cannula

Intervention Type OTHER

Non-invasive ventilation

Bi-level non-invasive ventilation via nasal mask

Intervention Type PROCEDURE

Room air

Room air applied via sham oxygen concentrator

Intervention Type OTHER

Placebo tablet

Placebo tablet (Mannitol) similar to acetazolamide

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Diamox Oxygen concentrator

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* percapillary pulmonary hypertension diagnosed by right heart catheterisation -- stable therapy and clinical condition for at least 4 weeks
* sleep disordered breathing with apnea/hypopnea index \> 10 events/h and/or median nocturnal oxygen saturation \<90%

Exclusion Criteria

* Pregnancy
* severe daytime hypoxemia (PaO2 \< 7.2 kPA)
* patients with predominantly obstructive sleep apnea.
Minimum Eligible Age

20 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Zurich

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

01 Studienregister MasterAdmins

Role: STUDY_DIRECTOR

UniversitaetsSpital Zuerich

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Respiratory Clinic, University Hospital of Zurich

Zurich, Canton of Zurich, Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

References

Explore related publications, articles, or registry entries linked to this study.

Ulrich S, Fischler M, Speich R, Bloch KE. Sleep-related breathing disorders in patients with pulmonary hypertension. Chest. 2008 Jun;133(6):1375-1380. doi: 10.1378/chest.07-3035. Epub 2008 Mar 13.

Reference Type BACKGROUND
PMID: 18339776 (View on PubMed)

Schumacher DS, Muller-Mottet S, Hasler ED, Hildenbrand FF, Keusch S, Speich R, Bloch KE, Ulrich S. Effect of oxygen and acetazolamide on nocturnal cardiac conduction, repolarization, and arrhythmias in precapillary pulmonary hypertension and sleep-disturbed breathing. Chest. 2014 Nov;146(5):1226-1236. doi: 10.1378/chest.14-0495.

Reference Type DERIVED
PMID: 24991933 (View on PubMed)

Ulrich S, Keusch S, Hildenbrand FF, Lo Cascio C, Huber LC, Tanner FC, Speich R, Bloch KE. Effect of nocturnal oxygen and acetazolamide on exercise performance in patients with pre-capillary pulmonary hypertension and sleep-disturbed breathing: randomized, double-blind, cross-over trial. Eur Heart J. 2015 Mar 7;36(10):615-23. doi: 10.1093/eurheartj/eht540. Epub 2013 Dec 23.

Reference Type DERIVED
PMID: 24366914 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CSRPH

Identifier Type: -

Identifier Source: org_study_id